FDA Designations Granted to PRAX-222, PRAX-562 for Epileptic Encephalopathies
Source: Pixabay.com

FDA Designations Granted to PRAX-222, PRAX-562 for Epileptic Encephalopathies

According to a recent press release from biopharmaceutical company Praxis Precision Medicines ("Praxis"), two of the company's drug candidates received either Orphan Drug or Rare Pediatric Disease designations for rare…

Continue Reading FDA Designations Granted to PRAX-222, PRAX-562 for Epileptic Encephalopathies
Injectable XP-0863 for Acute Repetitive Seizures Given Fast Track Designation
https://pixabay.com/en/epilepsy-seizure-stroke-headache-623346/

Injectable XP-0863 for Acute Repetitive Seizures Given Fast Track Designation

Recently, specialty pharmaceutical company Xeris Pharmaceuticals ("Xeris") announced that its injectable treatment XP-0863 received Fast Track designation for the treatment of patients with acute repetitive seizures. Xeris created this treatment…

Continue Reading Injectable XP-0863 for Acute Repetitive Seizures Given Fast Track Designation
Results from Two Studies Show Soticlestat Efficacy for CDD and Dup15q Syndrome
https://pixabay.com/en/epilepsy-seizure-stroke-headache-623346/

Results from Two Studies Show Soticlestat Efficacy for CDD and Dup15q Syndrome

  Developmental and epileptic encephalopathies (DEEs), or rare epilepsies, are somewhat of a newer topic. However, researchers are already making strides in creating treatments to address unmet patient needs. On…

Continue Reading Results from Two Studies Show Soticlestat Efficacy for CDD and Dup15q Syndrome
Three Young People With Chronic Illness Talk About the Challenges They Face
source: pixabay.com

Three Young People With Chronic Illness Talk About the Challenges They Face

  Three people with an eye on the future talk about their innermost feelings and the fact that their lives may be interrupted at any time by their chronic illness.…

Continue Reading Three Young People With Chronic Illness Talk About the Challenges They Face
MRFF Funding Promotes Treatment Development for Patients with Rare Diseases
https://pixabay.com/en/money-piggy-bank-coins-finance-2180338/

MRFF Funding Promotes Treatment Development for Patients with Rare Diseases

  When it comes to researching and finding treatments for rare diseases, funding plays a crucial role. Recently, the Medical Research Future Fund (MRFF) Stem Cell Therapies Mission presented Monash…

Continue Reading MRFF Funding Promotes Treatment Development for Patients with Rare Diseases
AI System Created To Speed Up Epileptic Diagnosis is Tested on Dravet Syndrome
source: pixabay.com

AI System Created To Speed Up Epileptic Diagnosis is Tested on Dravet Syndrome

As reported in Dravet Syndrome News, in a new study, researchers created an artificial intelligence system which could diagnose epileptic conditions more rapidly and easily than existing systems. Epilepsy is…

Continue Reading AI System Created To Speed Up Epileptic Diagnosis is Tested on Dravet Syndrome
ICYMI: A New Medical Device Invented by a Patient will Help Prevent Tongue Biting During Seizures
source: pixabay.com

ICYMI: A New Medical Device Invented by a Patient will Help Prevent Tongue Biting During Seizures

By Natalie Homan from In The Cloud Copy It’s estimated that about 3.4 million Americans have epilepsy, one of many conditions that can cause seizures. Seizures occur when there is…

Continue Reading ICYMI: A New Medical Device Invented by a Patient will Help Prevent Tongue Biting During Seizures
New Research Discovers Childhood Neurodegenerative Disorder
https://pixabay.com/en/nerve-cell-neuron-brain-neurons-2213009/

New Research Discovers Childhood Neurodegenerative Disorder

Researchers from the Murdoch Children’s Research Institute (MCRI) have recently discovered a previously unknown and uncharted neurodegenerative disorder. This rare disorder, which has not yet been named, affects children. It…

Continue Reading New Research Discovers Childhood Neurodegenerative Disorder

Updates from Marinus on Ganaxolone Trials for 3 Forms of Epilepsy

Marinus Pharmaceuticals has recently announced updates on its ganaxolone programs for tuberous sclerosis complex (TSC), PCDH19-related epilepsy (PCDH19-RE), and CDKL5 deficiency disorder (CDD). Ganaxolone Ganaxolone is a positive allosteric modulator…

Continue Reading Updates from Marinus on Ganaxolone Trials for 3 Forms of Epilepsy
Positive Results at End of Phase 3 Trial of Candidate Tuberous Sclerosis Complex Drug – CBD
cbd123 / Pixabay

Positive Results at End of Phase 3 Trial of Candidate Tuberous Sclerosis Complex Drug – CBD

According to a press release from the British biotechnology company GW Pharmaceuticals, the company has reported successful results at the conclusion of its phase 3 trial of tuberous sclerosis complex…

Continue Reading Positive Results at End of Phase 3 Trial of Candidate Tuberous Sclerosis Complex Drug – CBD
Ganaxolone Shows Potential in Treating CDKL5 and Reveals Biomarker in PCDH19 Epilepsy
stevepb / Pixabay

Ganaxolone Shows Potential in Treating CDKL5 and Reveals Biomarker in PCDH19 Epilepsy

According to a story from globenewswire.com, the biopharmaceutical company Marinus Pharmaceuticals, Inc., recently announced the presentation of Phase 2 clinical trial of the drug ganaxolone as a treatment for CDKL5…

Continue Reading Ganaxolone Shows Potential in Treating CDKL5 and Reveals Biomarker in PCDH19 Epilepsy
Iowa Doctors Hesitant to Certify Medical Cannabis Patients
https://pixabay.com/en/marijuana-colorado-marijuana-grow-269851/

Iowa Doctors Hesitant to Certify Medical Cannabis Patients

According to the Des Moines Register, Iowa has a new medical marijuana program rolling out on December 1st, but many doctors in the state have reservations about enrolling patients. Iowa's…

Continue Reading Iowa Doctors Hesitant to Certify Medical Cannabis Patients